News Quantified

CLYM – climb bio, inc. (US:NASDAQ)

Climb Bio to be Added to the Nasdaq Biotechnology Index

12/3

07:55 am

clym

Low

Climb Bio, Inc. (NASDAQ: CLYM) was upgraded by analysts at Leerink Partnrs to a "strong-buy" rating.

Climb Bio, Inc. (NASDAQ: CLYM) is now covered by analysts at Leerink Partners. They set an "outperform" rating and a $10.00 price target on the stock.

Climb Bio Reports Third Quarter 2024 Financial Results and Business Highlights

Climb Bio Appoints Douglas E. Williams, Ph.D., as Chair of the Board

Live Event: Join our next subscriber-only event: "The Data Driven Investor"

Register for our next upcoming LIVE training session, which will be hosted on Tuesday April 24th at 08:00 PM EST (New York Time).
Get your questions answered during the Q & A session.
For any support questions, contact our team: support@newsquantified.com

Click Here To Register For The Live Online Workshop

In short, News Quantified specializes in matching financial news with market data. We've analyzed 10s of millions of news events and know exactly which ones have an outsized impact on stock prices. So every single time a news item is released we know exactly what the average effect will be on a particular stock.

52 Week High	{{GetCompanyStockInfo.Week52HighValue}} {{GetCompanyStockInfo.Week52HighDate}}
52 Week Low	{{GetCompanyStockInfo.Week52LowValue}} {{GetCompanyStockInfo.Week52LowDate}}

Today’s Volatility	{{VolatilityStr}}
20 Day Volatility	{{Volatility20Str}}

Open	{{GetCompanyStockInfo.Open}}
Prior Close	{{GetCompanyStockInfo.PriorCloseValue}} {{GetCompanyStockInfo.PriorCloseDate}}